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O R I G I N A L A R T I C L E
Fresh whole blood use by forward surgical teams in Afghanistan
is associated with improved survival compared to component
therapy without platelets
Shawn C. Nessen, Brian J. Eastridge, Daniel Cronk, Robert M. Craig, Olle Berséus, Richard Ellison,
Kyle Remick, Jason Seery, Avani Shah, and Philip C. Spinella
BACKGROUND: In Afghanistan, a substantial portion of
resuscitative combat surgery is performed by US Army
forward surgical teams (FSTs). Red blood cells (RBCs)
and fresh frozen plasma (FFP) are available at these
facilities, but platelets are not. FST personnel frequently
encounter high-acuity patient scenarios without the
ability to transfuse platelets. An analysis of the use of
fresh whole blood (FWB) at FSTs therefore allows for an
evaluation of outcomes associated with this practice.
STUDY DESIGN AND METHODS: A retrospective
analysis was performed in prospectively collected data
from all transfused patients at six FSTs from December
2005 to December 2010. Univariate analysis was per-
formed, followed by two separate propensity score
analyses. In-hospital mortality was predicted with the
use of a conditional logistic regression model that incor-
porated these propensity scores. Subset analysis
included evaluation of patients who received uncross-
matched Type O FWB compared with those who
received type-specific FWB.
RESULTS: A total of 488 patients received a blood
transfusion. There were no significant differences in age,
sex, or Glasgow Coma Scale in those who received or
did not receive FWB. Injury Severity Scores were higher
in patients transfused FWB. In our adjusted analyses,
patients who received RBCs and FFP with FWB had
improved survival compared with those who received
RBCs and FFP without FWB. Of 94 FWB recipients, 46
FWB recipients (49%) were given uncrossmatched Type
O FWB, while 48 recipients (51%) received type-specific
FWB. There was no significant difference in mortality
between patients that received uncrossmatched Type O
and type-specific FWB.
CONCLUSIONS: The use of FWB in austere combat
environments appears to be safe and is independently
associated with improved survival to discharge when
compared with resuscitation with RBCs and FFP alone.
Mortality was similar for patients transfused
uncrossmatched Type O compared with ABO type-
specific FWB in an austere setting.
INTRODUCTION
With the end of combat operations in Iraq, attention to
Afghanistan has returned. There, a substantial portion of
resuscitative surgery has been performed by 20 personnel
US Army forward surgical teams (FSTs) or similar units.
Many of these teams have been split to more widely dis-
seminate surgical care platforms.1 FSTs doctrinally carry
only 20 units of red blood cells (RBCs), but currently in
Afghanistan they are augmented with fresh frozen plasma
(FFP) and some with cryoprecipitate. Platelets (PLTs) are
not available.1-4 The concept of damage control resuscita-
tion with the use of RBCs, FFP, and PLTs in balanced ratios
that approximate those of whole blood has been sup-
ported by several recent publications in the military and
civilian trauma literature.5-11 Although these studies are
retrospective in nature, the military has adopted a clinical
practice guideline recommending 1:1:1 unit ratios of these
blood components. In addition, current theater clinical
practice guidelines recommend the use of fresh whole
blood (FWB) be reserved for “casualties who are antici-
pated to require massive transfusion (10 or more units of
packed RBCs in 24 hr), for those with clinically significant
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shock or coagulopathy (e.g., bleeding with associated
metabolic acidosis, thrombocytopenia, or international
normalized ratio >1.5) when optimal component therapy
(e.g., apheresis PLTs and FFP) is unavailable or stored
component therapy is not adequately resuscitating a
patient with immediately life-threatening injuries.”12 Due
to the austerity of their environment, FST personnel fre-
quently encounter high-acuity patient scenarios without
the ability to transfuse PLTs. The use of FWB in these loca-
tions therefore generates an opportunity to evaluate out-
comes associated with whole blood transfusions. Current
US military doctrine states that FWB must be type specific
when transfused. In some remote settings where donors
are limited, this is not possible, and uncrossmatched Type
O FWB is transfused as a last resort. The objective of this
study is to examine the association of FWB use versus
use of component therapy (RBCs and FFP) only, with
in-hospital mortality in combat casualties admitted to
FSTs. Furthermore, we examine the association between
receipts of ABO type-specific FWB versus uncross-
matched Type O FWB on in-hospital mortality.
METHODS
The Institutional Review Board of the US Army Medical
Research and Materiel Command approved the retro-
spective analysis of all admission performance improve-
ment data of a convenience sample of six FSTs from
December 2005 to December 2010. These units were
chosen because they developed a comprehensive perfor-
mance improvement plan that included collection of
data regarding blood transfusion. The data were prospec-
tively collected by the individual FST units during the
5-year study period. Blood product utilization, mecha-
nism of injury, type of injuries, number and type of sur-
gical procedures performed, and ultimate patient
outcome were recorded. Demographic data including
patient status, sex, and age were also collected. Physi-
ologic variables including temperature, systolic blood
pressure (SBP), respiratory rate, and Glasgow Coma Scale
(GCS) at the time of initial patient presentation were col-
lected. Mechanism of injury was also collected and cat-
egorized into four broad areas: gunshot wound, blast
injury, motor vehicle crash, and burn. An Abbreviated
Injury Score and Injury Severity Score (ISS) were calcu-
lated for each transfused patient with the use of the Mili-
tary Abbreviated Injury Score 2005 (revised 2007). The
primary endpoint was mortality determined at inpatient
discharge from a Level V military facility for US forces or
discharge to a local national facility for Afghanis. Other
data collected included the number of blood products
transfused, activated recombinant factor VIIa (rFVIIa)
usage, patient age, and temperature on presentation.
Patients determined to have died within 1 hour of pre-
sentation were eliminated from the study in an attempt
to mitigate survivor bias. Afghani patients with penetrat-
ing head injuries with initial GCS of 7 were eliminated
as they were often treated expectantly. Statistical analysis
was performed by an independent statistician. Univari-
ate analysis was performed with the use of SAS 9.1 (SAS
Institute, Inc., Cary, NC). Two separate propensity score
analyses were performed utilizing STATA 11.2 (StataCorp
LP, College Station, TX). Variables that were associated
with the use of FWB in the univariate analysis were used
to calculate propensity scores. SBP at arrival to FST,
arrival temperature, use of rFVIIa, total RBCs, and total
FFP administered were used to calculate the propensity
score that was the probability of receiving FWB. The bal-
ancing property of the propensity scores was tested and
propensity scores were determined to be balanced in the
FWB and non-FWB groups. The propensity scores were
used in the logistic regression model predicting death,
adjusting for the ISSs and the Glasgow Coma Scores. The
propensity score was included as a continuous variable
in the first model. In the second analysis, propensity
scores were used to create strata or groups. Subjects were
grouped into six strata based on similarity of propensity
score and therefore have similar risk profile, without
regard to outcome or receipt of FWB. Following stratifi-
cation, death in each group was predicted with the use of
a conditional logistic regression. Conditional logistic
regression approach combines within-stratum effects
with between-stratum effects to estimate the overall FWB
effect on death.
RESULTS
A total of 488 patients met inclusion criteria. They received
2612 units of RBCs, 1566 units of FFP, and 416 units of
FWB. A total of 394 patients received blood transfusion
without receiving FWB and 94 patients received blood
transfusions that included FWB. Table 1 indicates that
ISSs and respiratory rate were significantly higher in
patients receiving FWB, while arrival SBP and temperature
were significantly lower. There was no significant differ-
ence in age, sex, or GCS in those who received or did not
receive FWB.
Predictably, patients receiving FWB also required sig-
nificantly more units of RBCs and FFP. These patients also
were more likely to receive rFVIIa and massive blood
transfusion (MBT) defined as 10 or more units of RBCs or
the equivalent combination of RBCs and FWB in the first
24 hours (Table 2). There was no statistical difference in
in-hospital mortality between study groups. In patients
who received FWB, the unadjusted mortality rate was
5.3% (5/94) for those transfused FWB and 8.8% (35/394)
for patients who did not receive FWB. Mechanism of
injury was similar between patients who received compo-
nent therapy with FWB and those who received only RBCs
and FFP (Table 3).
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Lower GCS, higher ISS, lower arrival SBP, and lower
arrival patient temperature were associated with death
(Table 4). Also, higher total RBC transfusion and higher
total blood product transfusion were associated with
death. Interestingly, total FFP and FWB transfused were not
associated with death. Consistent with previous reports,
patient mortality was associated with MBT and rFVIIa use
(Table 5). Two separate propensity score analyses were
performed with the use of a continuous variable and then
stratification method. With the use of continuous variable
logistic regression analysis, patients who received RBCs
and FFP with FWB had significantly improved survival
compared with those who received RBCs and FFP without
FWB, odds ratio (OR) (95% confidence interval [CI]) 0.096
(0.02-0.53). Higher ISS and lower GCS were associated with
increased mortality (Table 6). With the use of a stratified
propensity score analysis, FWB use was also associated
with improved survival OR (95% CI), 0.11 (0.02-0.78).
Higher ISS and lower GCS were also associated with
increased mortality (Table 7). A subset
analysis was performed for patients who
only received MBT. Ninety-four patients
received MBT, with 49 transfused FWB,
RBCs, and FFP and 45 patients received
only RBCs and FFP. The mortality rate in
those patients who received MBT with
RBCs, FFP, and FWB was 8.16% and those
who received MBT with RBCs and
FFP alone had a mortality of 26.67%
(p = 0.025). Another subset analysis was
performed in patients who received
FWB (n = 94) according to receipt of ABO
type-specific FWB (51%) or uncross-
matched Type O FWB (49%). There was
no statistical difference in in-hospital
mortality for patients who received
type-specific FWB (6.1%) compared with
those who received uncrossmatched
Type O FWB (6.7%) with three deaths in
each group. Data were not available to
report the ABO type of recipients who
received uncrossmatched Type O FWB. No transfusion
reactions were noted in patients who received FWB.
DISCUSSION
This is the first study to compare transfusion of RBCs and
FFP with FWB to patients who received only RBCs and FFP
at Level II or forward surgical facilities. Our results indi-
cate that, in a far forward setting during military opera-
tions, transfusion of RBCs, FFP, and FWB is independently
associated with improved in-hospital survival compared
with RBCs and FFP alone. As a result, not only does it
appear to be safe to transfuse FWB in this setting when
PLTs are not available but it may also improve outcomes
compared with the use of RBCs and FFP alone.
The coagulopathy associated with hemorrhaging
trauma patients has been long recognized.13,14 In Vietnam,
this clinical manifestation was sometimes referred to as
oozing syndrome, tomato juice syndrome, and red ink
TABLE 1. Admission vital sign and laboratory data by fresh whole blood (FWB) use
No FWB (n = 394) FWB (n = 94) p Value
Age (years) 25.6  11.5; 25 (20, 30); 371 28.1  9.7; 25 (22, 30); 81 0.08
US and/or coalition 53 (13.5) 14 (14.9) 0.715
Non-US and/or coalition 341 (86.5) 80 (85.1) 0.715
Male sex 375 (95.2) 90 (95.7) 1.00
GCS 13.8  2.7; 15 (14, 15); 394 13.2  3.4; 15 (14, 15); 93 0.11
ISS 19.6  9.3; 16.5 (16, 25); 394 22.4  8.9; 20 (16, 26); 94 0.008
Arrival SBP (mmHg) 110.5  27.1; 110 (95, 128); 388 99.9  30.1; 97 (80, 123); 94 <0.001
Arrival RR 22  8.2; 21 (16, 26); 383 25.2  9.7; 25 (18, 30); 94 0.005
Arrival temperature (°C) 36.4  0.8; 36.6 (36.2, 37.0); 373 36.1  1.2; 36.2 (35.6, 36.8); 83 0.005
Continuous variables reported as mean  SD; median (LowerQ, UpperQ); n.
Categorical variables reported as n (%).
GCS = Glasgow Coma Scale; ISS = Injury Severity Score; RR = respiratory rate; SBP = systolic blood pressure; SD = standard deviation.
TABLE 2. Blood products use by fresh whole blood (FWB)
No FWB (n = 394) FWB (n = 94) p Value
FWB (U) 0 4.4  4; 3 (2,6) <0.001
Total RBCs (U) 4.7  3.7; 4 (2, 6) 12.7  9.4; 10 (6, 16) <0.001
Total plasma (U) 2.6  2.7; 2 (0, 4) 10  7.1; 8 (5, 12) <0.001
Total blood products (U) 7.3  5.8; 6 (3, 10) 18.3  13.1; 14 (10, 24) <0.001
Factor VII given 23 (5.8) 24 (25.5) <0.001
Massive transfusion 46 (11.6) 49 (52.1) <0.001
Continuous variables reported as mean  SD; median (LowerQ, UpperQ).
Categorical variables reported as n (%).
RBCs = red blood cells; SD = standard deviation.
TABLE 3. Univariate comparison of mechanism of injury
Variable FWB (n = 94) No FWB (n = 394) p Value
Gunshot wound 48.9% 46.7% 0.696
Blast 43.6% 46.7% 0.590
Burns 0% 1.3% 0.272
Motor vehicle collision 0% 3.0% 0.087
Other 6.4% 3.0% 0.123
FWB = fresh whole blood.
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syndrome.15 This coagulopathic bleeding is associated
with the lethal triad of trauma, which also includes acido-
sis and hypothermia. However, coagulopathy is also rec-
ognized to occur early in trauma patients and is
exacerbated by blood loss, acidosis, hypothermia, con-
sumption, fibrinolysis, and dilution.9,10,16-20 As many as
one-third of combat trauma patients who require transfu-
sion are coagulopathic at their initial presentation to a
surgical facility.14
Recognizing the frequent futility of correcting coagul-
opathy and shock secondary to severe nonsurgical bleeding
with traditional resuscitative methods after it occurs, the
concept of hemostatic or damage control resuscitation
with all the components of whole blood has evolved. The
initial military research effort evaluated FFP transfused
concurrent with RBCs and which ratio of RBC:FFP was
associated with increased survival.5,20,21 The conclusions of
these studies were that transfusion of FFP concurrently
with RBCs in patients requiring large volumes of blood was
associated with improved survival and the RBC:FFP recom-
mended ratio was 1:1. As a result of these studies, damage
control resuscitation with the use of a 1:1 ratio of RBC and
FFP was adopted by all surgical units including FSTs and
combat support hospitals (CSHs) in Iraq and Afghanistan.
This was relatively easily done as FFP can be frozen and
stored for up to 1 year and was already available in both
theaters. PLTs were not available in theater until late 2004
and then only at the larger combat support hospitals.3
Largely due to the sporadic and inconsistent availabil-
ity of RBCs and FFP early in the war, FWB was frequently
used as a source of RBCs, FFP, and PLTs. Anecdotal reports
suggested that FWB was an excellent resuscitation fluid
TABLE 4. Admission vitals, patient demographics, and laboratory data by death status
Alive (n = 448) Dead (n = 40) p Value
Age (years) 25.9  11; 25 (20, 30); 417 28.3  13.5; 25 (21, 31); 35 0.23
Male sex 426 (95.1) 39 (97.5) 0.71
US and/or coalition 64 (14.3) 3 (7.5) 0.232
Non-US and/or coalition 384 (85.7) 37 (92.5) 0.232
GCS 14.1  2.3; 15 (14, 15); 447 9.4  4.7; 9.5 (5.5, 15); 40 <0.001
ISS 19.4  8.6; 16 (16, 25); 448 28.  12.1; 25 (19, 32); 40 <0.001
Arrival SBP (mmHg) 109.9  26.8; 110 (93, 128); 443 91.3  35; 84 (78, 109); 39 0.002
Arrival RR 22.5  8.4; 22 (16, 28); 438 24.1  11; 24 (17, 32); 39 0.41
Arrival temp (°C) 36.4  0.9; 36.6 (36.1, 37.0); 420 35.8  1.1; 35.8 (35.3, 36.4); 36 <0.001
Continuous variables reported as mean  SD; median (LowerQ, UpperQ); n.
Categorical variables reported as n (%).
GCS = Glasgow Coma Scale; ISS = Injury Severity Score; RR = respiratory rate; SBP = systolic blood pressure; SD = standard deviation.
TABLE 5. Blood products use by death status
Alive (n = 448) Dead (n = 40) p Value
FWB patient status 89 (19.9) 5 (12.5) 0.250
FWB (U) 0.8  2.2; 0 (0, 0); 448 1.4  4.7; 0 (0, 0); 40 0.43
Total RBCs (U) 5.8  5.5; 4 (2, 8); 448 10.5  10.4; 8 (4, 13); 40 0.008
Total plasma (U) 3.9  4.5; 3 (0, 6); 448 6.1  7.9; 4 (1.5, 6); 40 0.09
Total blood products (U) 8.9  8; 7 (3, 12); 448 15.1  14.2; 10 (6, 19) 42 0.01
Factor VII given 39 (8.7) 8 (20) 0.04
Massive transfusion 79 (17.6) 16 (40) 0.002
Continuous variables reported as mean  SD; median (LowerQ, UpperQ); n.
Categorical variables reported as n (%).
FWB = fresh whole blood; RBCs = red blood cells; SD = standard deviation.
TABLE 6. Propensity score used as continuous
variable in logistic regression predicting effect
of FWB on death
Odds ratio 95% CI p Value
FWB use 0.096 0.02,0.53 0.008
Injury Severity Score 1.07 1.03,1.11 <0.001
Glasgow Coma Score 0.72 0.65,0.79 <0.001
Propensity score 9.72 1.45,64.97 0.019
Arrival systolic blood pressure, arrival temperature, use of factor
VIIa, total red blood cells, and total plasma administered were
used to calculate propensity score.
CI = confidence interval; FWB = fresh whole blood.
TABLE 7. Stratified propensity score analysis
predicting the effect of the use of FWB on death
Odds ratio 95% CI p Value
FWB use 0.11 0.02, 0.78 0.03
Injury Severity Score 1.06 1.01, 1.11 0.01
Glasgow Coma Score 0.71 0.63, 0.79 <0.001
CI = confidence interval; FWB = fresh whole blood.
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and an early retrospective study by Spinella and colleagues
suggested that FWB combined with RBCs and FFP may be
superior to traditional component therapy consisting of
RBCs, FFP, and apheresis PLTs.23 However, a subsequent
retrospective review by Perkins and colleagues compared
MBT patients who received either apheresis PLTs or FWB
and found that adjusted survival approached significance
(p = 0.06) at 24 hours with no difference at 30 days, and a
higher unadjusted incidence of ARDS in the FWB group
was noted.22 Based largely on these studies, a theater prac-
tice guideline was published, which recommended the use
of FWB for circumstances when PLTs were not available.
However, when component therapy provided inadequate
resuscitation, the clinical practice guideline supported the
use of FWB at the discretion of the surgeon.23
Afghanistan is a mature theater and apheresis PLTs
are now available at CSHs, also referred to by North Atlan-
tic Treaty Organization (NATO) forces as Role III facilities.2
However, in Afghanistan, FSTs provide initial surgery to
the combat injured in the majority of locations. The FST
was designed to provide a surgical capability to a maneu-
vering combat brigade and the ability to do this success-
fully has been well reported in the literature.24-28 In an
attempt to provide surgical capability to as many locations
as possible the 20 personnel FSTs have been split. This
practice although initially questioned has been shown to
be successful with excellent outcomes achieved by appro-
priately trained teams.1,28 PLTs are not available at either
full or split FSTs. This is problematic as the main purpose
of the FST is to provide damage control surgery and resus-
citation. Under these circumstances, FWB is commonly
used due to its PLT constituent and almost always in con-
junction with RBCs and FFP. There are additional theoreti-
cal benefits of FWB compared with components, which
include fresh RBCs that may have increased efficacy at
delivering oxygen as well as reduced harmful storage
lesion effects. In addition, FWB is a more concentrated
product (less anticoagulants and additives) than whole
blood reconstituted from stored components.
Of the 488 patients in this study who received blood
transfusion, 94 received FWB (19.26%). Patients who
received FWB on average received 4.43 units of FWB, 8.27
units of RBCs, 5.59 units of FFP, and a mean of 18.27 units
of total blood products. This shows that in large part
patients who received FWB received it in the context of
large volume if not MBT resuscitation.
In this study, patients transfused before the fall of
2008 usually received uncrossmatched Type O. It is likely
that many of the patients who received Type O blood in
this setting were Type O patients. During this period, in
the forward setting, where there was no capacity to
perform ABO typing of donors, it was not possible to
determine how many casualties who received transfusion
uncrossmatched Type O blood received Type ABO-specific
blood. After this time, the theater policy mandated only
transfusing type-specific FWB, and FSTs were augmented
with type and cross capability. This study showed no dif-
ference in mortality between patients receiving uncross-
matched FWB compared with when type-specific FWB
was intentionally transfused. The safety of transfusing
uncrossmatched or Type O FWB in dire circumstances
when type-specific FWB cannot be provided requires
further study. The current US military policy prohibiting
this practice may be increasing the risk of mortality for
patients unnecessarily. No data exist that the authors are
aware of that indicate that the use of Type O FWB as a last
resort when ABO type-specific blood is not available is
associated with increased risk of poor outcomes. While no
transfusion reactions were noted in FWB recipients, the
signs and symptoms of a transfusion reaction can easily
be missed during massive hemorrhage and MBT. The
additive risk introduced by the transfusion of Type O
blood with incompatible plasma ABO antibodies is a
severe intravascular hemolytic transfusion reaction
(IHTR). In contrast to other transfusion reactions, IHTR
constitutes an acute clinically recognizable entity charac-
terized by physical discomfort, chest and/or abdominal
pain, fever, hypotension, dyspnea, and appearance at the
beginning of the transfusion. Depending on the trans-
fused volume, later symptoms may include macroscopic
hematuria, disseminated intravascular coagulation, and
circulatory failure. In spite of the wide use of Type O whole
blood during World War II, no reports of IHTR were
observed until 1944 when a few were reported.29 The reac-
tions were not fatal but led to a US policy of screening the
Type O donors for ABO plasma antibodies and excluding
those with high titers from serving as “universal donors.”30
During the later Korean and Vietnam Wars, 52,000 and
230,300 transfusions were reported without any IHTR
caused by a compatible transfusion. There were however
some IHTRs as a result of incompatible blood transfusions
due to administrative errors.31
Until very recently, there was no doctrinal capability
to type and crossmatched blood at an FST and the com-
plexity of managing a blood bank capable of typing and
crossmatching blood was beyond the reasonable expecta-
tions of these small teams, especially in the early days of
combat operations.4,32 This practice is currently prohib-
ited by the current US Army FWB clinical practice guide-
line in favor of type and crossmatched blood, despite no
data indicating that the practice is associated with worse
outcomes.1,4,35-37
Our study has limitations inherent to retrospective
analyses. A convenience sample may introduce sampling
bias. More importantly, our results may be affected by sur-
vival bias as it takes a mean of 30-45 minutes to receive the
first unit of FWB. In this study, we eliminated patients who
died within the first hour of treatment at the FST, which
minimizes survival bias. The majority of those who died
did so after transfer; however, due to the transfer of
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Afghani patients to local facilities, determining the cause
of death was not always possible, which makes it difficult
to draw any conclusions on the long-term effects of FWB
transfusion.
CONCLUSIONS
The use of FWB in austere combat environments appears
to be safe and is independently associated with improved
survival when compared with resuscitation with RBCs and
FFP alone. Mortality was similar for patients transfused
uncrossmatched Type O FWB compared with ABO type-
specific FWB in an austere setting. Further studies evalu-
ating outcomes related to the use of uncrossmatched Type
O FWB in these settings are warranted.
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